Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2316268 | 1.00 | XIAP (0.40) | XIAPELANE | |
| SCHEMBL2318127 | 0.90 | ELANE (0.37) | XIAPELANE | |
| SCHEMBL2318118 | 0.90 | ELANE (0.37) | XIAPELANE | |
| SCHEMBL2209205 | 0.79 | XIAP (0.38) | XIAP | |
| SCHEMBL2209197 | 0.79 | XIAP (0.38) | XIAP | |
| SCHEMBL2211147 | 0.78 | ELANE (0.43) | ELANE | |
| SCHEMBL2211151 | 0.78 | ELANE (0.43) | ELANE | |
| SCHEMBL2319269 | 0.77 | ELANE (0.45) | XIAPELANE | |
| SCHEMBL2319274 | 0.77 | ELANE (0.45) | XIAPELANE | |
| SCHEMBL2319353 | 0.76 | IL1B (0.44) | XIAPELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989441-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | claimed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | claimed |
| EP-1902065-A2 | CYCLIC AMIDE DERIVATIVES INHIBITORS OF THE INHIBITOR OF APOPTOSIS PROTEINS, THEIR PREPARATION, AND THEIR USE | Novartis AG (CH) | 2008-03-26 | — | — | EP | claimed |
| WO-2006133147-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-12-14 | — | — | WO | claimed |
| US-20110281845-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| US-20110281845-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| US-7989441-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-7989441-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | disclosed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069294-A1 | Organic Compounds | XIAP, BAX, MCL1 | XIAP 1/4885ELANE 2303/4885 |
| US-20110281845-A1 | ORGANIC COMPOUNDS | XIAP, BAX, MCL1 | XIAP 1/4885ELANE 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.